Business Context and Reporting Period
ADC Therapeutics SA filed this Form 6-K for May 2020. On May 19, 2020, the company received the initial disbursement under a previously announced facility agreement with Deerfield Partners, L.P. and certain affiliates.
Key Financial and Capital Structure Information
- ADC Therapeutics issued $65.0 million aggregate principal amount of senior secured convertible notes to Deerfield.
- The proceeds were received as the initial disbursement of senior secured convertible term loans.
- The filing does not provide revenue, profit, cash flow, margin, cash balance, total debt, liquidity runway, interest rate, maturity, conversion price, or collateral details.
Material Changes Versus the Prior Comparable Period
The filing reports a material increase in secured borrowing and potential equity dilution through the issuance of convertible notes. No comparative-period operating or financial results are included.
Guidance, Outlook, Risks, and Unusual Items
- The notes are senior secured and convertible, creating both repayment obligations and potential dilution to existing shareholders.
- The filing does not provide management guidance, an updated outlook, use-of-proceeds detail, covenants, default provisions, or additional risk commentary.
- The form of the senior secured convertible note is included as Exhibit 99.1.
Facts Investors Should Verify
- Interest rate, maturity date, conversion terms, conversion price, and potential share dilution.
- Collateral package, financial and other covenants, and restrictions under the Facility Agreement.
- Whether additional term-loan disbursements are available or required and the aggregate facility commitment.
- Intended use of the $65.0 million proceeds and the company’s resulting cash runway and liquidity position.